Compare BYND & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BYND | DRUG |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Pharmaceuticals and Biotechnology |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 447.4M | 364.8M |
| IPO Year | 2019 | N/A |
| Metric | BYND | DRUG |
|---|---|---|
| Price | $0.91 | $82.12 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $1.70 | ★ $83.00 |
| AVG Volume (30 Days) | ★ 85.8M | 157.9K |
| Earning Date | 11-10-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $290,565,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $23.18 |
| 52 Week High | $7.69 | $97.75 |
| Indicator | BYND | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 39.00 | 56.87 |
| Support Level | $0.96 | $77.80 |
| Resistance Level | $1.26 | $89.71 |
| Average True Range (ATR) | 0.11 | 8.40 |
| MACD | -0.00 | -0.81 |
| Stochastic Oscillator | 0.67 | 32.52 |
Beyond Meat Inc is a provider of plant-based meat company offering a portfolio of revolutionary plant-based meats. It builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating plant-based meat product It has products such as burgers, sausage, ground beef, jerky, meatballs and chicken. The company generates revenue from sales of its products to the customers across mainstream grocery, mass merchandiser, club store, convenience store and natural retailer channels and various food-away-from-home channels, including restaurants, foodservice outlets and schools, mainly in the United States.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.